These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 30055128)

  • 21. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.
    Gaig C; Martí MJ; Ezquerra M; Rey MJ; Cardozo A; Tolosa E
    J Neurol Neurosurg Psychiatry; 2007 Jun; 78(6):626-8. PubMed ID: 17210620
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Garrido A; Fairfoul G; Tolosa ES; Martí MJ; Green A;
    Ann Clin Transl Neurol; 2019 Jun; 6(6):1024-1032. PubMed ID: 31211166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
    Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
    Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.
    Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ
    Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.
    Lubben N; Brynildsen JK; Webb CM; Li HL; Leyns CEG; Changolkar L; Zhang B; Meymand ES; O'Reilly M; Madaj Z; DeWeerd D; Fell MJ; Lee VMY; Bassett DS; Henderson MX
    Transl Neurodegener; 2024 Mar; 13(1):13. PubMed ID: 38438877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
    Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
    Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effect of p.G2019S Mutation in the
    Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
    J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
    Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
    Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.
    Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL
    Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.
    Guerreiro PS; Huang Y; Gysbers A; Cheng D; Gai WP; Outeiro TF; Halliday GM
    J Mol Med (Berl); 2013 Apr; 91(4):513-22. PubMed ID: 23183827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons.
    Henderson MX; Changolkar L; Trojanowski JQ; Lee VMY
    J Parkinsons Dis; 2021; 11(3):1187-1196. PubMed ID: 33720852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain and Cerebrospinal Fluid α-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
    Garrido A; Fairfoul G; Tolosa E; Marti MJ; Ezquerra M; Green AJE
    Mov Disord; 2023 Feb; 38(2):333-338. PubMed ID: 36471633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling Parkinson's disease in LRRK2 mice: focus on synaptic dysfunction and the autophagy-lysosomal pathway.
    Albanese F; Domenicale C; Volta M; Morari M
    Biochem Soc Trans; 2022 Feb; 50(1):621-632. PubMed ID: 35225340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.
    Plowey ED; Cherra SJ; Liu YJ; Chu CT
    J Neurochem; 2008 May; 105(3):1048-56. PubMed ID: 18182054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation.
    Pischedda F; Cirnaru MD; Ponzoni L; Sandre M; Biosa A; Carrion MP; Marin O; Morari M; Pan L; Greggio E; Bandopadhyay R; Sala M; Piccoli G
    Brain; 2021 Jun; 144(5):1509-1525. PubMed ID: 33876242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease.
    Gaig C; Vilas D; Infante J; Sierra M; García-Gorostiaga I; Buongiorno M; Ezquerra M; Martí MJ; Valldeoriola F; Aguilar M; Calopa M; Hernandez-Vara J; Tolosa E
    PLoS One; 2014; 9(10):e108982. PubMed ID: 25330404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.